2.59  -0.09 (-3.36%)		09-25 16:00
Open: 2.68 High: 2.715 Volume: 513,035		Pre. Close: 2.68 Low: 2.585 Market Cap: 179(M)

Short term
Mid term
Targets	6-month :	3.73	1-year :	4.16
Resists	First :	3.19	Second :	3.56
Pivot price	2.92
Supports	First :	2.58	Second :	2.15
MAs	MA(5) :	2.76	MA(20) :	2.97
	MA(100) :	2.2	MA(250) :	3.77
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	3.4	D(3) :	9.3
RSI	RSI(14): 38.3
52-week	High :	7.8	Low :	1.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PEPG ] has closed below the lower bollinger band by 0.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.72 - 2.74	2.74 - 2.75
Low:	2.54 - 2.56	2.56 - 2.58
Close:	2.56 - 2.6	2.6 - 2.62

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Sat, 19 Sep 2026
PEPG Should I Buy - Intellectia AI

Mon, 24 Aug 2026
PepGen (PEPG) Q2 2026 Results: EPS Comes in Above Forecast on the Day; Post-Earnings: Shares Close 3.46% Higher in the Current Update - Product Revenue Analysis - careplusvn.com

Tue, 11 Aug 2026
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Moomoo

Sat, 08 Aug 2026
Is PepGen (NASDAQ:PEPG) In A Good Position To Invest In Growth? - simplywall.st

Thu, 06 Aug 2026
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace

Thu, 25 Jun 2026
PEPG Forecast — Price Target — Prediction for 2027 - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	69 (M)
Shares Float	36 (M)
Held by Insiders	0.2 (%)
Held by Institutions	82.8 (%)
Shares Short	4,390 (K)
Shares Short P.Month	4,530 (K)

EPS	-1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.73
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-39.2 %
Return on Equity (ttm)	-75.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.09
Qtrly Earnings Growth	0 %
Operating Cash Flow	-69 (M)
Levered Free Cash Flow	-43 (M)

PE Ratio	-2.59
PEG Ratio	0
Price to Book value	1.49
Price to Sales	0
Price to Cash Flow	-2.59

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.